Metsera (NASDAQ:MTSR) Price Target Raised to $62.00 at Guggenheim

Metsera (NASDAQ:MTSR) had its target price increased by Guggenheim from $56.00 to $62.00 in a research report released on Tuesday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other research analysts also recently commented on MTSR. Cantor Fitzgerald initiated coverage on Metsera in a research note on Tuesday, February 25th. They set an “overweight” rating for the company. Bank of America initiated coverage on Metsera in a research note on Tuesday, February 25th. They issued a “buy” rating and a $38.00 price target for the company. Finally, Evercore ISI initiated coverage on Metsera in a research note on Tuesday, February 25th. They issued an “outperform” rating for the company.

Metsera Stock Up 15.5%

Shares of MTSR opened at $35.10 on Tuesday. The stock’s fifty day moving average is $23.40. Metsera has a 12 month low of $12.30 and a 12 month high of $37.99.

Metsera (NASDAQ:MTSR) last issued its quarterly earnings data on Monday, May 12th. The company reported ($1.03) EPS for the quarter.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of MTSR. Strs Ohio bought a new position in shares of Metsera in the first quarter worth $76,000. New York State Common Retirement Fund bought a new position in Metsera during the first quarter valued at about $131,000. Corebridge Financial Inc. bought a new position in Metsera during the first quarter valued at about $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Metsera during the first quarter valued at about $248,000. Finally, MetLife Investment Management LLC bought a new position in Metsera during the first quarter valued at about $254,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.